FDA approves Abbvie's preventative migraine tablet

Another preventive migraine treatment is ready for the US market, after the FDA accepted Abbvie's drug Qulipta on Tuesday.

Photo: Abbvie / PR

Competition on the market for migraine prevention is heating up as yet another treatment has slipped through the eye of the needle at the US Food and Drug Administration (FDA).

Abbvie informs in a press release that the FDA has granted marketing approval for Qulipta. Like other migraine medicines that have been launched over the past few years, Abbvie's drug is a calcitonin gene-related peptide (CGRP) receptor antagonist, which means the substance targets the CGRP receptor believed to play a crucial role in pain transmission.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs